Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

Clinical anti-drug-antibody (ADA) responses represent a substantial obstacle to the development of efficacious therapeutic antibodies. The enhanced ADA production against the idiotype (Id) often displayed by cancer immunotherapy antibodies (CitAbs) can lead to exposure loss and subsequently affect a...

Descripción completa

Detalles Bibliográficos
Autores principales: Egli, Jerome, Heiler, Stefan, Weber, Felix, Steiner, Guido, Schwandt, Timo, Bray-French, Katharine, Klein, Christian, Fenn, Sebastian, Lotz, Gregor P., Opolka-Hoffmann, Eugenia, Kraft, Thomas E., Petersen, Laetitia, Moser, Rebecca, DeGeer, Jonathan, Siegel, Michel, Finke, Daniela, Bessa, Juliana, Iglesias, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673943/
https://www.ncbi.nlm.nih.gov/pubmed/36394299
http://dx.doi.org/10.1080/19420862.2022.2143009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673943/
https://www.ncbi.nlm.nih.gov/pubmed/36394299
http://dx.doi.org/10.1080/19420862.2022.2143009

Ejemplares similares